Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
ACS Chem Neurosci
2013 Dec 18;412:1524-9. doi: 10.1021/cn4001236.
Show Gene links
Show Anatomy links
"Deconstruction" of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter.
Kolanos R
,
Solis E
,
Sakloth F
,
De Felice LJ
,
Glennon RA
.
???displayArticle.abstract???
Synthetic cathinones, β-keto analogues of amphetamine (or, more correctly, of phenylalkylamines), represent a new and growing class of abused substances. Several such analogues have been demonstrated to act as dopamine (DA) releasing agents. Methylenedioxypyrovalerone (MDPV) was the first synthetic cathinone shown to act as a cocaine-like DA reuptake inhibitor. MDPV and seven deconstructed analogues were examined to determine which of MDPV's structural features account(s) for uptake inhibition. In voltage-clamped (-60 mV) Xenopus oocytes transfected with the human DA transporter (hDAT), all analogues elicited inhibitor-like behavior shown as hDAT-mediated outward currents. Using hDAT-expressing mammalian cells we determined the affinities of MDPV and its analogues to inhibit uptake of [3H]DA by hDAT that varied over a broad range (IC50 values ca. 135 to >25,000 nM). The methylenedioxy group of MDPV made a minimal contribution to affinity, the carbonyl group and a tertiary amine are more important, and the extended α-alkyl group seems most important. Either a tertiary amine, or the extended α-alkyl group (but not both), are required for the potent nature of MDPV as an hDAT inhibitor.
Baumann,
Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products.
2013, Pubmed
Baumann,
Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products.
2013,
Pubmed
Baumann,
The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue.
2012,
Pubmed
Cameron,
Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter.
2013,
Pubmed
,
Xenbase
Cameron,
Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of "bath salts," produce opposite effects at the human dopamine transporter.
2013,
Pubmed
,
Xenbase
Dal Cason,
Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs.
1997,
Pubmed
Drug Enforcement Administration, Department of Justice,
Schedules of controlled substances: extension of temporary placement of methylone into schedule I of the Controlled Substances Act. Final order.
2012,
Pubmed
Drug Enforcement Administration, Department of Justice,
Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order.
2011,
Pubmed
Eshleman,
Substituted methcathinones differ in transporter and receptor interactions.
2013,
Pubmed
Fantegrossi,
In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity.
2013,
Pubmed
Glennon,
Methcathinone: a new and potent amphetamine-like agent.
1987,
Pubmed
Iwamoto,
Na+, Cl-, and pH dependence of the human choline transporter (hCHT) in Xenopus oocytes: the proton inactivation hypothesis of hCHT in synaptic vesicles.
2006,
Pubmed
,
Xenbase
Kalix,
Further evidence for an amphetamine-like mechanism of action of the alkaloid cathinone.
1986,
Pubmed
Machaca,
Asymmetrical distribution of Ca-activated Cl channels in Xenopus oocytes.
1998,
Pubmed
,
Xenbase
Marusich,
Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice.
2012,
Pubmed
Meltzer,
1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.
2006,
Pubmed
Ramsey,
Serotonin transporter function and pharmacology are sensitive to expression level: evidence for an endogenous regulatory factor.
2002,
Pubmed
,
Xenbase
Simmler,
Pharmacological characterization of designer cathinones in vitro.
2013,
Pubmed
Spiller,
Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States.
2011,
Pubmed
Wang,
Electrophysiological effect of fluoxetine on Xenopus oocytes heterologously expressing human serotonin transporter.
2006,
Pubmed
,
Xenbase